IRIS
MAIO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.078
EU - Europa 7.972
AS - Asia 1.027
SA - Sud America 30
OC - Oceania 29
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 23.147
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.047
IE - Irlanda 2.547
GB - Regno Unito 1.815
IT - Italia 933
FR - Francia 792
UA - Ucraina 743
CN - Cina 609
SE - Svezia 577
VN - Vietnam 280
DE - Germania 224
ES - Italia 137
FI - Finlandia 105
RU - Federazione Russa 51
IN - India 50
AU - Australia 28
CA - Canada 27
BR - Brasile 26
TR - Turchia 17
HK - Hong Kong 15
BE - Belgio 13
SA - Arabia Saudita 11
JP - Giappone 9
GR - Grecia 7
NL - Olanda 7
ZA - Sudafrica 7
SG - Singapore 6
AE - Emirati Arabi Uniti 5
ID - Indonesia 4
SK - Slovacchia (Repubblica Slovacca) 4
HU - Ungheria 3
PK - Pakistan 3
AM - Armenia 2
BD - Bangladesh 2
BO - Bolivia 2
CH - Svizzera 2
IM - Isola di Man 2
IR - Iran 2
PA - Panama 2
PH - Filippine 2
PT - Portogallo 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GE - Georgia 1
IQ - Iraq 1
KH - Cambogia 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MA - Marocco 1
MK - Macedonia 1
MS - Montserrat 1
MX - Messico 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PL - Polonia 1
RS - Serbia 1
TH - Thailandia 1
TN - Tunisia 1
Totale 23.147
Salva come PNG Salva come JPEG
Città #
Fairfield 3.008
Dublin 2.544
Southend 1.625
Woodbridge 1.439
Ashburn 1.284
Wilmington 1.132
Seattle 1.107
Houston 1.093
Cambridge 1.036
Jacksonville 748
Princeton 531
Ann Arbor 398
San Mateo 357
Siena 347
Dong Ket 280
Beijing 224
Dearborn 195
San Diego 191
Chandler 171
New York 146
Málaga 133
Shanghai 97
Helsinki 92
London 71
Rome 54
San Francisco 54
Milan 44
Nanjing 42
Florence 40
Norwalk 40
Delhi 36
Hefei 27
Boardman 25
Toronto 24
Fremont 22
Salvador 20
Nanchang 19
Jinan 18
Phoenix 18
Asciano 17
Palermo 17
Catania 16
Guangzhou 16
Kunming 15
Cascina 14
Kilburn 14
Brussels 13
Empoli 13
Redwood City 13
Riyadh 11
Hong Kong 10
Melbourne 10
Montevarchi 10
Canberra 9
Hounslow 9
Islington 9
Prescot 9
Shenyang 9
Trieste 9
Acton 8
Tianjin 8
Chengdu 7
Chiswick 7
Johannesburg 7
Sydney 7
Tokyo 7
Venezia 7
Changsha 6
Marano Vicentino 6
Naples 6
Singapore 6
Zhengzhou 6
Chicago 5
Fuzhou 5
Haikou 5
Labico 5
Lappeenranta 5
Los Angeles 5
Lucca 5
Mezzolombardo 5
Novara 5
Padova 5
San Giovanni Valdarno 5
Shaoxing 5
Wandsworth 5
Altamura 4
Bratislava 4
Brolo 4
Chennai 4
Chongqing 4
Düsseldorf 4
Ferentino 4
Menlo Park 4
New Bedfont 4
Pistoia 4
Redmond 4
Salerno 4
Sesto Fiorentino 4
Washington 4
Amsterdam 3
Totale 19.187
Salva come PNG Salva come JPEG
Nome #
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 209
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 208
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial 177
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 171
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 167
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 165
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 158
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 149
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 146
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 135
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 133
Biomolecular strategies for therapeutic intervention in cancer 132
Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors 126
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 126
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 125
The biology of cancer testis antigens: putative function, regulation and therapeutic potential 122
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide 121
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 117
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 117
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study 113
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 112
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 112
CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells 111
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 109
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 107
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 106
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy 106
Future perspectives in melanoma research. Meeting report from the “Melanoma research: a bridge from Naples to the world. Napoli, December 5th-6th 2011” 105
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial 105
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893 102
Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls 102
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 102
Biology and clinical applications of CD40 in cancer treatment 102
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 101
THE ITALIAN EXPERIENCE ON THE FEASIBILITY AND SAFETY OF IPILIMUMAB THERAPY IN PRETREATED METASTATIC MELANOMA PATIENTS 99
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010" 98
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 97
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 97
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy 97
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 96
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody 96
Predictors of responses to immune checkpoint blockade in advanced melanoma 96
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis 95
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 95
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma 95
null 95
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma 95
Implementing liquid biopsies into clinical decision making for cancer immunotherapy 95
Adjuvant pembrolizumab versus placebo in resected stage III melanoma 95
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 95
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 94
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 94
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma 94
Melanoma as a model tumour for immuno-oncology 93
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009 93
Signaling by HLA class II antigens on B cells 93
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 92
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy 92
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells 91
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 91
Epigenetic drugs as immunomodulators for combination therapies in solid tumors 91
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge 91
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability 90
Whole genome methylation profiles as independent markers of survival in stage IIIc melanoma patients 90
Immunotherapy targeting immune check-point(s) in brain metastases 90
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) 89
The future of mesothelioma treatment: time to shift gear 89
Epigenetically‐Regulated Therapeutic Tumor‐Associated Antigens 87
Epigenetically-regulated Tumor-Associated Antigens in melanoma 87
Effects of cyclophosphamide and IL-2 on regulatory CD4(+) T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response 87
null 87
Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-arm, phase 2, multicentre study 86
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial 86
Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study) 85
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications 85
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172) 85
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 84
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients 83
The role of BRAF V600 mutation in melanoma 83
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy 83
Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs) 83
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 83
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells 83
Peptide-based vaccines for cancer therapy 83
HLA and prognostic factors in primary breast cancer 83
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 83
Anti-Tyrosinase Antibodies participate in the immune-response to vaccination with antiidiotypic antibodies mimicking the the High-Molecular-Weight-Melanoma-Associated-Antigen 82
Introduction: Cancer epigenetics and epigenetic treatment of cancer 82
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study 82
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial 82
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study) 81
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF(V600)-mutated Metastatic Melanoma 81
Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity 80
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study) 80
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology 80
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond 80
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria 79
Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma 79
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 79
Integrating immune checkpoint blockade with anti-neo/mutated antigens reactivity to increase the clinical outcome of immunotherapy 79
Totale 10.224
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.126
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.126
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019120 0 0 0 0 0 0 0 0 0 18 55 47
2019/20208.550 39 16 24 1.132 1.167 931 1.293 1.378 946 807 248 569
2020/20215.623 171 733 400 407 318 810 270 1.100 211 421 195 587
2021/20223.523 179 419 382 96 44 159 121 152 223 521 373 854
2022/20233.174 413 175 652 404 76 704 87 126 160 146 170 61
2023/20243.088 96 81 277 89 83 1.019 1.239 110 60 34 0 0
Totale 24.232